Design of a novel pyrrolidine scaffold utilized in the discovery of potent and selective human β₃ adrenergic receptor agonists

A novel class of human β₃-adrenergic receptor agonists was designed in effort to improve selectivity and metabolic stability versus previous disclosed β₃-AR agonists. As observed, many of the β₃-AR agonists seem to need the acyclic ethanolamine core for agonist activity. We have synthesized derivati...

Full description

Saved in:
Bibliographic Details
Published in:Bioorganic & medicinal chemistry letters 2011-03, Vol.21 (6), p.1865-1870
Main Authors: Morriello, Gregori J, Wendt, Harvey R, Bansal, Alka, Salvo, Jerry Di, Feighner, Scott, He, Jiafang, Hurley, Amanda L, Hreniuk, Donna L, Salituro, Gino M, Reddy, Marat Vijay, Galloway, Sheila M, McGettigan, Katherine K, Laws, George, McKnight, Crystal, Doss, George A, Tsou, Nancy N, Black, Regina M, Morris, Judy, Ball, Richard G, Sanfiz, Anthony T, Streckfuss, Eric, Struthers, Mary, Edmondson, Scott D
Format: Article
Language:English
Subjects:
Adrenergic beta-Agonists - chemistry
Adrenergic beta-Agonists - pharmacology
agonists
Biological and medical sciences
Catecholaminergic system
chemistry
Crystallography, X-Ray
dogs
Drug Discovery
ethanolamine
Humans
Macaca mulatta
Medical sciences
metabolites
Models, Molecular
Neuropharmacology
Neurotransmitters. Neurotransmission. Receptors
pharmacokinetics
Pharmacology. Drug treatments
Pyrrolidines - chemistry
rats
Receptors, Adrenergic, beta-3 - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A novel class of human β₃-adrenergic receptor agonists was designed in effort to improve selectivity and metabolic stability versus previous disclosed β₃-AR agonists. As observed, many of the β₃-AR agonists seem to need the acyclic ethanolamine core for agonist activity. We have synthesized derivatives that constrained this moiety by introduction of a pyrrolidine. This unique modification maintains human β₃ functional potency with improved selectivity versus ancillary targets and also eliminates the possibility of the same oxidative metabolites formed from cleavage of the N–C bond of the ethanolamine. Compound 39 exhibited excellent functional β₃ agonist potency across species with good pharmacokinetic properties in rat, dog, and rhesus monkeys. Early de-risking of this novel pyrrolidine core (44) via full AMES study supports further research into various new β₃-AR agonists containing the pyrrolidine moiety.
ISSN:0960-894X
1464-3405
DOI:10.1016/j.bmcl.2010.12.087